Merck Oncology Strategy: With First-Line Lung Data, A New Day Dawns For Keytruda
Executive Summary
Merck claims to have the broadest clinical development program for an anti-PD-1/L1 drug, with more than 270 trials under way testing Keytruda in 30 tumor types and 100 combinations.
You may also be interested in...
Opdivo's Failure In First-Line Lung Cancer Prompts Rethink On Trial Endpoints
Merck's Keytruda gains huge advantage in first-line lung cancer as Bristol's stumble in patients with lower expression of PD-L-1 biomarker raises questions about cut-off levels in trials.
J&J And Sanofi Team Up On Phase III E. Coli Vaccine
Sanofi will pay $175m up front for rights to commercialize J&J’s potential first-in-class vaccine against E. coli. The two companies will share profits.
ICER Hands CMS A Drug Price Negotiation Cheat Sheet
The drug price assessment group ran cost analyses on two of the first 10 drugs selected for Medicare price negotiations, Eliquis and Xarelto, and submitted the report to the US government.